MAX
Company Analysis Apellis Pharmaceuticals, Inc.
1. Summary
Disadvantages
- Price (18.39 $) is higher than fair price (2.81 $)
- Dividends (0%) are below the sector average (0.5%).
- The stock's return over the last year (0%) is lower than the sector average (14.97%).
- Current debt level 45.23% has increased over 5 years from 39.32%.
- The company's current efficiency (ROE=6.05%) is lower than the sector average (ROE=95.3%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Apellis Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -8.4% | -12.6% | 0.2% |
| 90 days | -30.6% | -8.1% | -4% |
| 1 year | 0% | 15% | 18.1% |
APLS vs Sector: Apellis Pharmaceuticals, Inc. has significantly underperformed the "Healthcare" sector by -14.97% over the past year.
APLS vs Market: Apellis Pharmaceuticals, Inc. has significantly underperformed the market by -18.09% over the past year.
Stable price: APLS is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: APLS with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (18.39 $) is higher than the fair price (2.81 $).
Price is higher than fair: The current price (18.39 $) is 84.7% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (103.52) is higher than that of the sector as a whole (26.63).
P/E vs Market: The company's P/E (103.52) is higher than that of the market as a whole (-88.36).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (6.26) is lower than that of the sector as a whole (238.73).
P/BV vs Market: The company's P/BV (6.26) is lower than that of the market as a whole (81.84).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (2.31) is lower than that of the sector as a whole (128.13).
P/S vs Market: The company's P/S indicator (2.31) is lower than that of the market as a whole (116.29).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (45.58) is higher than that of the sector as a whole (-21.78).
EV/Ebitda vs Market: The company's EV/Ebitda (45.58) is higher than that of the market as a whole (-79.49).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -20.6% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-20.6%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-28.94%).
6.4. ROE
ROE vs Sector: The company's ROE (6.05%) is lower than that of the sector as a whole (95.3%).
ROE vs Market: The company's ROE (6.05%) is lower than that of the market as a whole (23.33%).
6.6. ROA
ROA vs Sector: The company's ROA (2.08%) is higher than that of the sector as a whole (-4.47%).
ROA vs Market: The company's ROA (2.08%) is lower than that of the market as a whole (4.25%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-121.89%) is lower than that of the sector as a whole (-0.11%).
ROIC vs Market: The company's ROIC (-121.89%) is lower than that of the market as a whole (8.8%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 4.76% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 20.01.2026 | Watson David O. General Counsel |
Sale | 19.79 | 4 898 | 2 475 |
| 20.01.2026 | Chopas James George Officer |
Purchase | 19.79 | 1 437 | 726 |
| 20.01.2026 | Sullivan Timothy Eugene Officer |
Purchase | 19.79 | 5 723 | 2 892 |
| 20.01.2026 | Baumal Caroline Officer |
Purchase | 19.79 | 3 725 | 1 882 |
| 20.01.2026 | Deschatelets Pascal Officer |
Purchase | 19.79 | 1 799 | 909 |
Based on sources: porti.ru
